Table 1 Summary of patient demographics

From: Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

Demographic

Total ( n =49)

Age, median (range)

57 (26–76)

Sex, n (%)

 Male

20 (41)

 Female

29 (59)

WHO performance status, n (%)

 0

25 (51)

 1

23 (47)

 2

1 (2)

Primary tumour location, n (%)

 Colorectal

16 (33)

 Uterus

6 (12)

 Head and neck

5 (10)

 Skin/soft tissue

4 (8)

 Ovary

3 (6)

 Renal

3 (6)

 Other

12 (25)

Locally advanced, n (%)

 Yes

15 (31)

 No

34 (69)

Prior treatment, n (%)

 Radiotherapy

27 (55)

 Chemotherapy

44 (90)

 Prior regimens

 

1–2

21 (43)

3–6

17 (35)

>6

9 (18)

  1. Abbreviation: WHO=World Health Organization.